Project Name：Paliperidone palmitate 

Registration Classification：3+6

Formulations and specifications ：Sustained-release injection 0.25ml: 25mg; 0.5ml: 50mg; 0.75ml: 75mg; 1.0ml: 100mg; 1.5ml: 150mg. 

Indications：For schizophrenia in acute and maintenance stage, injection once a month.

Original Research Company：Ortho-McNeil-Janssen Pharmaceuticals Inc. 

Progress ：Pharmaceutical Research in progress